Loading...
Please wait, while we are loading the content...
Similar Documents
Long-Term Survival and Value of$ ^{18}$F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with$ ^{177}$Lu-DOTATATE
| Content Provider | MDPI |
|---|---|
| Author | Rodrigues, Margarida Winkler, Kevin-Klaus Svirydenka, Hanna Nilica, Bernhard Uprimny, Christian Virgolini, Irene |
| Copyright Year | 2021 |
| Description | Peptide receptor radionuclide therapy (PRRT) has been recognized as a promising therapy against neuroendocrine tumors (NETs). The use of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in NETs has been a matter of controversy. The purpose of this study was to evaluate the long-term survival and efficacy of a second PRRT course with 177Lu-DOTATE in patients with advanced gastroenteropancreatic (GEP) NETs. Furthermore, the value of 18F-FDG PET/CT in these patients was evaluated. 40 patients with GEP NETs who underwent two PRRT courses with 177Lu-DOTATATE and combined examinations with 68Ga-DOTA-TOC and 18F-FDG PET/CT were evaluated. After the second PRRT course, two patients (5.0%) were in partial remission, 21 patients (52.5%) in stable disease and 17 patients (42.5%) had progressive disease. The median overall survival was 122.10 months. After the second PRRT course, the median overall survival was significantly higher (p = 0.033) in the 18F-FDG-negative group compared to the 18F-FDG-positive group (145.50 versus 95.06 months, respectively). The median time to progression was 19.37 months. In conclusion, a second PRRT course with 177Lu-DOTATE is an effective treatment approach for GEP NET patients with disease progression. A change in 18F-FDG status after PRRT may predict the disease course and survival. Patients who are 18F-FDG-negative have a significantly longer overall survival than those who are 18F-FDG-positive. |
| Starting Page | 198 |
| e-ISSN | 20751729 |
| DOI | 10.3390/life11030198 |
| Journal | Life |
| Issue Number | 3 |
| Volume Number | 11 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-03-04 |
| Access Restriction | Open |
| Subject Keyword | Life Endocrinology and Metabolism Neuroendocrine Tumors Peptide Receptor Radionuclide Therapy 177lu-dotate 18f-fdg Pet |
| Content Type | Text |
| Resource Type | Article |